

Early Withdrawal of Calcineurin Inhibitors and Everolimus in Kidney Transplant Recipients Preserves Renal Function

American Journal of Transplantation

10, 2252-2262

DOI: [10.1111/j.1600-6143.2010.03128.x](https://doi.org/10.1111/j.1600-6143.2010.03128.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Does Early (CNI) Conversion Lead to Eternal (Renal) Salvation?. American Journal of Transplantation, 2010, 10, 2189-2190.	2.6	4
3	m-TOR inhibitors: What role in liver transplantation?. Journal of Hepatology, 2011, 55, 1441-1451.	1.8	61
4	Conversion to Everolimus in Liver Transplant Patients With Renal Dysfunction. Transplantation Proceedings, 2011, 43, 2307-2310.	0.3	8
5	Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. Hepatic Medicine: Evidence and Research, 2011, 3, 53.	0.9	2
6	The use of everolimus in pediatric liver transplant recipients: First experience in a single center. Pediatric Transplantation, 2011, 15, 510-514.	0.5	37
7	Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transplant International, 2011, 24, 1216-1230.	0.8	84
8	Cyclosporine monotherapy in cardiac transplantation. Transplantation Reviews, 2011, 25, 131-135.	1.2	10
9	Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis. Liver Transplantation, 2011, 17, 905-913.	1.3	71
12	Renal dysfunction and the liver transplant recipient; novel strategies for determination of reversibility and renal protective therapies pretransplant and posttransplant. Current Opinion in Organ Transplantation, 2012, 17, 225-229.	0.8	6
13	A Comprehensive Review of Everolimus Clinical Reports. Transplantation, 2012, 94, 659-668.	0.5	60
14	Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitorâ€‘Based Immunosuppression? A Systematic Review and Meta-Analysis. Transplantation, 2012, 94, 1208-1217.	0.5	86
15	Sirolimus â€‘ It doesnâ€™t deserve its bad Rap(a). Journal of Hepatology, 2012, 56, 285-287.	1.8	16
16	Everolimus and Enteric-Coated Mycophenolate Sodium Ab Initio after Liver Transplantation: Midterm Results. Transplantation Proceedings, 2012, 44, 1942-1945.	0.3	11
17	Review article: Use of induction therapy in liver transplantation. Transplantation Reviews, 2012, 26, 246-260.	1.2	29
18	Immunological advantages of everolimus versus cyclosporin A in liverâ€‘transplanted recipients, as revealed by polychromatic flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 303-311.	1.1	16
19	Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation. Liver International, 2012, 32, 179-188.	1.9	44
20	A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantationâ€‘PROTECT. American Journal of Transplantation, 2012, 12, 1855-1865.	2.6	165
21	Do kidney histology lesions predict longâ€‘term kidney function after liver transplantation?. Clinical Transplantation, 2012, 26, 927-934.	0.8	6

#	ARTICLE	IF	CITATIONS
22	Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation. <i>Liver Transplantation</i> , 2012, 18, 188-194.	1.3	27
23	Everolimus Monotherapy or Combined Therapy in Liver Transplantation: Indications and Results. <i>Transplantation Proceedings</i> , 2013, 45, 1971-1974.	0.3	27
24	Everolimus: A Guide to Its Use in Liver Transplantation. <i>BioDrugs</i> , 2013, 27, 407-411.	2.2	6
25	Kidney Disease in the Setting of Liver Failure: Core Curriculum 2013. <i>American Journal of Kidney Diseases</i> , 2013, 62, 1198-1212.	2.1	26
26	Calcineurin inhibitors in liver transplantation – still champions or threatened by serious competitors?. <i>Liver International</i> , 2013, 33, 656-665.	1.9	45
27	Early use of renal-sparing agents in liver transplantation: A closer look. <i>Liver Transplantation</i> , 2013, 19, 826-842.	1.3	21
28	Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study. <i>American Journal of Transplantation</i> , 2013, 13, 1734-1745.	2.6	158
29	Calcineurin Inhibitor-Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare-the-Nephron Trial. <i>Liver Transplantation</i> , 2013, 19, 675-689.	1.3	87
30	Preserving Flow in Liver Transplant Recipients: mTOR Inhibitors Everolimus and Sirolimus Are Not Peas From a Pod. <i>American Journal of Transplantation</i> , 2013, 13, 1633-1635.	2.6	3
32	The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. <i>Journal of Transplantation</i> , 2014, 2014, 1-45.	0.3	57
33	The role of everolimus in liver transplantation. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 329.	1.0	35
34	Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. <i>World Journal of Transplantation</i> , 2014, 4, 133.	0.6	18
35	The role of mTOR inhibitors in the prevention of organ rejection in adult liver transplant patients: a focus on everolimus. <i>Transplant Research and Risk Management</i> , 0, , 31.	0.7	0
36	Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , 2014, 18, 48.	1.0	9
37	Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2014, 46, 2035-2044.	0.6	34
38	Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. <i>Transplant International</i> , 2014, 27, 1039-1049.	0.8	145
39	Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation. <i>American Journal of Transplantation</i> , 2014, 14, 701-710.	2.6	85
40	De Novo Sirolimus and Reduced-Dose Tacrolimus Versus Standard-Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial. <i>American Journal of Transplantation</i> , 2014, 14, 356-366.	2.6	82

#	ARTICLE	IF	CITATIONS
41	Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant. <i>Clinical Transplantation</i> , 2014, 28, 662-668.	0.8	15
42	Everolimus in liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 578-582.	0.8	19
43	Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience. <i>Hepatology International</i> , 2014, 8, 137-145.	1.9	22
44	Everolimus-based immunosuppression in a case of ABO-incompatible liver transplantation with calcineurin inhibitor-related posterior occipital syndrome. <i>Transplant International</i> , 2014, 27, e84-e86.	0.8	9
46	Immunosuppression. <i>Clinics in Liver Disease</i> , 2014, 18, 687-716.	1.0	14
47	Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors. <i>Liver International</i> , 2014, 34, 1513-1521.	1.9	18
48	Current strategies for immunosuppression following liver transplantation. <i>Langenbeck's Archives of Surgery</i> , 2014, 399, 981-988.	0.8	17
49	Experience of Using Everolimus in the Early Stage of Living Donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 744-748.	0.3	23
50	Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus. <i>Transplantation</i> , 2015, 99, 1455-1462.	0.5	109
51	Impact of different immunosuppressive regimens on the health-related quality of life following orthotopic liver transplantation. <i>Clinical Transplantation</i> , 2015, 29, 1081-1089.	0.8	8
52	Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. <i>Liver Transplantation</i> , 2015, 21, 1056-1065.	1.3	35
53	Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 118.	0.7	10
54	Everolimus in de novo liver transplant recipients: a systematic review. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 461-469.	0.6	23
55	Everolimus Plus Mycophenolate Mofetil as Initial Immunosuppression in Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 90-92.	0.3	13
56	mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?. <i>Transplantation Reviews</i> , 2015, 29, 93-102.	1.2	47
57	mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. <i>Transplantation Reviews</i> , 2015, 29, 168-174.	1.2	56
58	Postoperative Intensive Care Management in Adults. , 2015, , 866-894.		2
59	Long-Term Toxicity of Immunosuppressive Therapy. , 2015, , 1354-1363.		9

#	ARTICLE	IF	CITATIONS
60	Everolimus is safe within the first month after liver transplantation. <i>Transplant Immunology</i> , 2015, 33, 146-151.	0.6	9
61	Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. <i>Journal of Transplantation</i> , 2016, 2016, 1-11.	0.3	43
62	Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation. <i>Transplantation</i> , 2016, 100, 621-629.	0.5	21
63	Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?. <i>Clinical Transplantation</i> , 2016, 30, 279-288.	0.8	9
64	Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. <i>Transplant International</i> , 2016, 29, 961-973.	0.8	57
65	Selection and use of immunosuppressive therapies after liver transplantation: current German practice. <i>Clinical Transplantation</i> , 2016, 30, 487-501.	0.8	22
66	Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. <i>Transplantation Proceedings</i> , 2016, 48, 3109-3111.	0.3	0
67	Use of everolimus in liver transplantation: The French experience. <i>Transplantation Reviews</i> , 2016, 30, 161-170.	1.2	19
68	Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2016, 18, 819-831.	0.7	64
69	The Role of mTOR Inhibitors in Solid Organ Transplantation. , 2016, , 293-315.		1
70	Safety and Efficacy of Early Everolimus When Calcineurin Inhibitors Are Not Recommended in Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2016, 48, 2506-2509.	0.3	6
71	The efficacy and safety of mammalian target of rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 315-320.	0.4	10
72	Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. <i>Immunotherapy</i> , 2017, 9, 197-206.	1.0	1
73	Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. <i>American Journal of Transplantation</i> , 2017, 17, 1843-1852.	2.6	79
74	Liver Transplantation: the Role of Metabolic Syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 316-331.	0.3	7
75	Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 123-136.	1.0	30
76	Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD011639.	1.5	35
77	Recomendaciones de uso de everolimus en el trasplante hepático. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 629-640.	0.2	2

#	ARTICLE	IF	CITATIONS
78	Recommendations of everolimus use in liver transplant. <i>Gastroenterology & Hepatology (English)</i> 2018, 10, 100-107. / <i>Overlook</i> 10 Tf 5	0.0	1
79	Use of Everolimus in Liver Transplantation. <i>Transplantation</i> , 2017, 101, 239-251.	0.5	54
80	Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2017, 31, e12872.	0.8	40
81	Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2018, 50, 175-183.	0.3	9
82	Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. <i>Diabetes Therapy</i> , 2018, 9, 521-543.	1.2	55
83	Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. <i>Transplantation Reviews</i> , 2018, 32, 142-150.	1.2	10
84	Cardiovascular Disease Outcomes Related to Early Stage Renal Impairment After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 1096-1107.	0.5	26
85	Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 237-244.	0.7	23
86	mTOR Inhibition and Clinical Transplantation. <i>Transplantation</i> , 2018, 102, S19-S26.	0.5	16
87	Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients. <i>Journal of Nephrology</i> , 2019, 32, 129-137.	0.9	10
88	Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13179.	1.7	13
89	Management of diabetes mellitus in patients undergoing liver transplantation. <i>Pharmacological Research</i> , 2019, 141, 556-573.	3.1	23
90	Systematic review with meta-analysis: sirolimus or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1260-1273.	1.9	60
93	Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial. <i>Liver Transplantation</i> , 2019, 25, 242-251.	1.3	27
94	mTOR inhibitors in pediatric liver transplant recipients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 403-409.	0.7	11
95	Renal disease in the allograft recipient. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101690.	1.0	9
96	Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. <i>Hepatology International</i> , 2020, 14, 930-943.	1.9	37
97	Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry. <i>Liver Transplantation</i> , 2020, 26, 1465-1476.	1.3	23

#	ARTICLE	IF	CITATIONS
98	Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2020, 52, 556-558.	0.3	3
99	Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation. <i>Human Immunology</i> , 2021, 82, 81-88.	1.2	4
100	Metabolic and Renal Effects of Mammalian Target of Rapamycin Inhibitors Treatment After Liver Transplantation: Real-Life Single-Center Experience. <i>Transplantation Proceedings</i> , 2021, 53, 221-227.	0.3	2
101	Kidney disease in children with heart or liver transplant. <i>Pediatric Nephrology</i> , 2021, 36, 3595-3605.	0.9	5
102	Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	10
103	Kidney Failure after Liver Transplantation. <i>Transplantation</i> , 2021, 2, 315-335.	0.3	3
104	A single-center, open-label, randomized crossover study to evaluate the pharmacokinetics and bioavailability of once-daily prolonged-release formulations of tacrolimus in de novo liver transplant recipients. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1771-1780.	1.3	3
105	Immunosuppression: Induction and immediate maintenance in liver transplant recipients. <i>Gastroenterology, Hepatology and Endoscopy Practice</i> , 2021, 1, 89.	0.1	0
106	Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Transplantation Proceedings</i> , 2021, 53, 148-158.	0.3	9
107	Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression. <i>Annals of Transplantation</i> , 2018, 23, 751-757.	0.5	19
108	Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience. <i>Annals of Gastroenterology</i> , 2018, 31, 613-620.	0.4	4
109	Prognostic value of endogenous and exogenous metabolites in liver transplantation. <i>Biomarkers in Medicine</i> , 2020, 14, 1165-1181.	0.6	2
110	Liver transplantation: Current status and challenges. <i>World Journal of Gastroenterology</i> , 2016, 22, 4438.	1.4	217
111	Management of immunosuppressant agents following liver transplantation: Less is more. <i>World Journal of Hepatology</i> , 2016, 8, 148.	0.8	16
112	Use of everolimus in liver transplantation. <i>World Journal of Hepatology</i> , 2017, 9, 990.	0.8	22
113	Multiple indications for everolimus after liver transplantation in current clinical practice. <i>World Journal of Transplantation</i> , 2014, 4, 122.	0.6	9
114	Medical Course and Complications After Liver Transplantation. , 2019, , 169-179.		0
116	The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation. <i>International Journal of Health Sciences</i> , 2018, 12, 78-87.	0.4	1

#	ARTICLE	IF	CITATIONS
118	Kidney Disease After Nonkidney Solid Organ Transplant. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 577-586.	0.6	0
120	Immunosuppressive Drugs in Liver Transplant: An Insight. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1557-1571.	0.4	20
121	Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. <i>Pharmacotherapy</i> , 2022, 42, 599-633.	1.2	36
122	Impact of very early introduction of everolimus on liver regeneration after partial liver transplantation in rats. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 0, , .	1.4	0
123	Safety and efficacy of everolimus initiation from the first month after liver transplantation: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2023, 37, .	0.8	3